Hypoparathyroidism usually responds to oral active vitamin D and calcium, but, although rare, some patients do not respond to this treatment. A 45–year–old male presented to our medical unit with classical oral treatment–resistant hypocalcemia, hyperphosphatemiaand hypoparathyroidism. Teriparatide was given subcutaneously .In conclusion, subcutaneous injection of teriparatide is a safe and effective treatment modality to ensure normocalcemic conditions in patients with classical treatment–resistant hypoparathyroidism.